Navigation Links
Moffitt researchers: Darwin's principles say cancer will always evolve to resist treatment
Date:6/21/2012

According to researchers at Moffitt Cancer Center, cancer is subject to the evolutionary processes laid out by Charles Darwin in his concept of natural selection. Natural selection was the process identified by Darwin by which nature selects certain physical attributes, or phenotypes, to pass on to offspring to better "fit" the organism to the environment.

As applied to cancer, natural selection, a key principle of modern biology, suggests that malignancies in distinct "microhabitats" promote the evolution of resistance to therapies. However, these same evolutionary principles of natural selection can be applied to successfully manage cancer, say Moffitt researchers who published an opinion piece in a recent issue of Nature Reviews Cancer.

"Understanding cancer as a disease starts with identifying crucial environmental forces and corresponding adaptive cellular strategies," said Robert A. Gatenby, M.D., chair of the Department of Diagnostic Imaging. "Cancer is driven by environmental selection forces that interact with individual cellular adaptive strategies."

Cancer cell development, like any natural selection (or Darwinian) process, is governed by environmental selection forces and cellular adaptive strategies, the authors wrote. Investigating cancer and its proliferation through genetic changes and ignoring the adaptive landscape is most likely futile. Under "selective pressure" of chemotherapy, in this case the "adaptive landscape," resistant populations of cancer cells invariably evolve.

The authors say that tumors can be thought of as "continents" populated by multiple cellular species that adapt to regional variations in environmental selection forces. Their strategy in offering this metaphor, they wrote, is to "integrate microenvironmental factors at work during cancer's progression" into the model of the evolution of cancer and, particularly, the evolution of drug resistance.

"Hundreds of mutations can be found in tumors," said co-author Daniel Verduzco, Ph.D., a post-doctoral fellow at Moffitt. "The physical environment of the early tumor is constantly changing, often in response to inflammation."

This reality should remind us, they wrote, that natural selection selects for phenotype, for observable physical characteristics, and that natural selection forces at work in local environments causes populations to change phenotypically rather than genotypically.

The authors point out that for most patients with advanced cancers - even when there is a well-known target and a highly specific drug - response to therapy is fleeting owing to the evolution and proliferation of a resistant population of cancer cells.

While targeted therapies have been among the most recent approaches to treating cancer, the authors suggest that the vast changes in the genetics of tumors via mutations reduce the effectiveness of targeted therapies and are a reason why targeted therapies cease to work.

"The emergence of resistance is predictable and inevitable as a fundamental property of carcinogenesis," Gatenby said. "However, this fundamental fact is commonly ignored in the design of treatment strategies. The emergence of drug resistance is rarely, if ever, dealt with until it occurs."

In an effort to develop patient-specific, long-term therapeutic strategies, the authors contend that resistance should be anticipated. By "anticipation" in action, they mean developing "adaptive therapies" prior to the emergence of resistance.

Cancer cells, they wrote, can only adapt to immediate selection forces. Cancer cells cannot anticipate future environmental conditions or evolutionary dynamics. This concept, said the authors, may provide an advantage when designing new therapies by "directing" the natural selection processes to prevent the outgrowth of resistant cancer populations and so improve outcomes.

"This potentially unifying theory places the evolution of cancer within a dynamically active landscape," said Robert J. Gillies, chair of the Department of Cancer Imaging and Metabolism, and program leader of Experimental Therapeutics. "The outcome is cancer's heterogeneity - those variations that negatively affect targeted therapies to control cancer.

"Recognizing that evolutionary dynamics are an essential component of carcinogenesis itself can lead to development of appropriate therapeutic strategies," Gillies said. "For example, knowing ahead of time that resistant cancers are likely to emerge provides us with lead time to develop preventive or adaptive therapeutic approaches. We have recently completed studies with our colleagues, Dr. Ariosto Silva , showing that evolutionarily informed therapies can forestall the emergence of resistant tumors for a very long time."

The authors conclude that we can use our understanding of evolution to strategically direct natural selection toward preventing the outgrowth of resistant cancer populations and, in so doing, improve outcomes.


'/>"/>
Contact: Patty Kim
patty.kim@moffitt.org
813-745-7322
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Moffitt researchers find cancer therapies affect cognitive functioning among breast cancer survivors
2. Moffitt Cancer Center researchers: Quality of life as important as quantity of life
3. Moffitt Cancer Center researchers working at frontiers of melanoma research
4. Moffitt researchers find adolescents with cancer concerned about their future reproductive health
5. Moffitt researcher publishes book on nutritional management of cancer treatment effects
6. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
7. Researchers creating designer lymph nodes based on Moffitts Total Cancer Care initiative
8. Moffitt Cancer Center researchers identify drivers of sarcoma growth and survival
9. Moffitt Cancer Center researchers develop and test new anti-cancer vaccine
10. Moffitt researcher, colleagues find success with new immune approach to fighting some cancers
11. Study Suggests Vaccine May Help Kids With Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... 24, 2017 , ... Accordant Technology, a trusted IT solutions ... an analytics-first approach, layered with machine learning, that provides real-time visibility into the ... cloud to the edge. Through the new partnership, customers get the real-time situational ...
(Date:5/24/2017)... ... ... Lowe is a sought after actor, and also serves as the host of the ... all aspects of life, and a new segment is being developed on podiatry, which ... is essential to people’s overall well-being, and if viewers have feet problems, they may ...
(Date:5/24/2017)... ... , ... Technique, technique, technique – with a dash of common sense. Those ... and exercise or simply lifting heavy objects, advises Dr. Kaliq Chang, interventional pain management ... says. “Improper technique in lifting anything heavy or an attempt to lift too much ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... Axiad ... organizations, today announced CIO Applications magazine has named the company a “Top 25 ... use of the Cloud to help organizations simply and proactively address potential cybersecurity threats ...
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge, MA, May ... since 2009, according to a Workers Compensation Research Institute (WCRI) study, a contrast ... North Carolina System: CompScope™ Benchmarks, 17th Edition looks at indemnity and medical ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... Israel , May 4, 2017  DarioHealth Corp. ... mobile health and big data solutions, today announced that ... A&D Company, and STI Technologies Limited to lower diabetes ... immediately. Through STI,s innoviCares card, which is available throughout ... , DarioHealth customers will be eligible for additional savings ...
(Date:5/3/2017)... May 3, 2017  Kalorama Information notes that ... percent next year and this is projected to ... stem cell (HSCT) or bone marrow transplants require ... are well-suited for this task. This according to ... Kalorama Information. The various PCR-based methodologies, Sanger sequencing ...
(Date:5/2/2017)... , May 2, 2017  George Clinical, a ... region, and Vector Oncology, a ... and data analytics, formally announced today that George Clinical ... the transaction has the dual purpose of strengthening ... led oncology trial delivery solutions throughout the ...
Breaking Medicine Technology: